BRAF and colorectal carcinoma: For instance, the identification of the BRAF V600E mutation in a subset of colorectal cancers (CRC) created much enthusiasm for treatment with vemurafenib, but subsequent studies showed that vemurafenib is not active in CRC because of the presence of a growth factor mediated feedback loop [2].